Chemomab Therapeutics Ltd. entered into a merger agreement on July 7, 2026, to redomicile into the U.S. and merge with Scipher Medicine Corporation, with Scipher becoming a wholly owned subsidiary. The transaction includes a concurrent PIPE investment of at least $30 million, reflecting a combined company valuation of $150 million, and Chemomab shareholders will receive contingent value rights (CVRs) for the nebokitug asset. The merger is expected to be completed in the fourth calendar quarter of 2026. Chemomab Therapeutics Ltd. is a biotechnology company focused on developing therapeutic solutions.